☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
77-0390628
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification Number)
|
308 Dorla Court, Suite 206 Zephyr Cove, Nevada
|
89448
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of Class
|
Trading Symbol
|
Name of Exchange on Which Registered
|
Common Stock, par value $0.0001 per share
|
VHC
|
NYSE American LLC
|
Large accelerated filer ☐
|
Accelerated filer ☒
|
Smaller reporting company ☐
|
Non-accelerated filer ☐
|
Emerging growth company ☐
|
• |
We have been awarded damages in the amount of $439.7 million in the VirnetX Inc. v. Cisco Systems, Inc. et al. (Case 6:10-CV-00417-LED) (“Apple I”) litigation and $595.9
million in the VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED) (“Apple II”) litigation. Taken together, these statements may imply that we may soon receive over $1 billion in cash. Recently United States Court of Appeals for the
Federal Circuit (“USCAFC”) issued a Rule 36 order affirming the District Court Judgment in the Apple I case. However, (1) Apple has appealed the awards in both of the Apple I and Apple II litigations and the court’s or jury’s decisions
may be reversed or amended upon appeal, or (2) we may be unsuccessful in our appeal of certain actions by the patent trial and appeals board that have been initiated by Apple or other parties if any of these occur, they may have the
effect of thwarting entirely, or reducing and delaying payments to us. The continuation of these litigations is distracting to our management and expensive, and this distraction and expense may continue.
|
• |
We have undertaken activities to commercialize our products and patent portfolio in and outside the United States. These statements may imply that the worldwide market for
our commercialized products is large and will result in significant future revenues for us. However, commercialization of products such as ours are subject to significant obstacles and risks, including but not limited to a perception by
some potential partners and customers that they should await the outcome of the Apple I and Apple II litigations before entering or considering to enter any agreement with us, and that or other factors may lead us to be unsuccessful in
obtaining further licensing agreements or making arrangements or entering contracts which create significant future revenues for us.
|
Page
|
||
1
|
||
1
|
||
1
|
||
2
|
||
2 |
||
3 |
||
4
|
||
5
|
||
12
|
||
15 |
||
16 |
||
17 |
||
17 |
||
19 |
||
28 |
||
29 |
||
30 |
As of
March 31, 2019
|
As of
December 31, 2018
|
|||||||
ASSETS
|
(unaudited) | |||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
5,227
|
$
|
7,611
|
||||
Investments available for sale
|
3,033
|
1,803
|
||||||
Accounts receivables
|
8
|
6
|
||||||
Prepaid expenses and other current assets
|
599
|
718
|
||||||
Total current assets
|
8,867
|
10,138
|
||||||
Other assets
|
1,924
|
1,604
|
||||||
Property and equipment, net
|
7
|
9
|
||||||
Total assets
|
$
|
10,798
|
$
|
11,751
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable and accrued liabilities
|
$
|
1,279
|
$
|
1,050
|
||||
Accrued payroll and related expenses
|
223
|
277
|
||||||
Other liabilities, current
|
171 |
140
|
||||||
Income tax liability
|
395
|
396
|
||||||
Total current liabilities
|
2,068
|
1,863
|
||||||
Other liabilities
|
—
|
—
|
||||||
Total liabilities
|
2,068
|
1,863
|
||||||
Commitments and contingencies (Note 4)
|
—
|
—
|
||||||
Stockholders’ equity:
|
||||||||
Preferred stock, par value $0.0001 per share Authorized: 10,000,000 shares at March 31, 2019 and
December 31, 2018, Issued and outstanding: 0 shares at March 31, 2019 and December 31, 2018
|
—
|
—
|
||||||
Common stock, par value $0.0001 per share Authorized: 100,000,000 shares at March 31, 2019 and December 31, 2018, Issued and outstanding: 68,104,001 shares and 66,879,847 shares, at March 31, 2019 and December 31, 2018, respectively
|
7
|
7
|
||||||
Additional paid-in capital
|
212,766
|
208,317
|
||||||
Accumulated deficit
|
(204,030
|
)
|
(198,422
|
)
|
||||
Accumulated other comprehensive loss
|
(13
|
)
|
(14
|
)
|
||||
Total stockholders’ equity
|
8,730
|
9,888
|
||||||
Total liabilities and stockholders’ equity
|
$
|
10,798
|
$
|
11,751
|
Three Months Ended
|
||||||||
March 31,
2019
|
March 31,
2018
|
|||||||
Revenue
|
$
|
8
|
$
|
6
|
||||
Operating expense:
|
||||||||
Research and development
|
936
|
1,005
|
||||||
Selling, general and administrative
|
4,706
|
6,609
|
||||||
Total operating expense
|
5,642
|
7,614
|
||||||
Loss from operations
|
(5,634
|
)
|
(7,608
|
)
|
||||
Interest income, net
|
28
|
8
|
||||||
Loss before taxes
|
(5,606
|
)
|
(7,600
|
)
|
||||
Provision for income taxes
|
(2
|
)
|
(5
|
)
|
||||
Net loss
|
$
|
(5,608
|
)
|
$
|
(7,605
|
)
|
||
Basic and diluted loss per share
|
$
|
(0.08
|
)
|
$
|
(0.13
|
)
|
||
Weighted average shares outstanding basic and diluted
|
67,596
|
60,150
|
Three Months Ended
|
||||||||
March 31,
2019
|
March 31,
2018
|
|||||||
Net loss
|
$
|
(5,608
|
)
|
$
|
(7,605
|
)
|
||
Other comprehensive gain (loss), net of tax:
|
||||||||
Change in equity adjustment from foreign currency translation, net of tax
|
—
|
—
|
||||||
Change in unrealized gain (loss) on investments, net of tax
|
1
|
1
|
||||||
Total other comprehensive gain (loss) net of tax
|
1
|
1
|
||||||
Comprehensive loss
|
$
|
(5,607
|
)
|
$
|
(7,604
|
)
|
Common Stock
|
Additional
Paid-in
Capital
|
Accumulated
Deficit
|
Accumulated
Other
Comprehensive
Loss
|
Total
Stockholders’
Equity
(Deficit)
|
||||||||||||||||||||
Shares
|
Amount
|
|||||||||||||||||||||||
Balance at December 31, 2017
|
59,051,978
|
$
|
6
|
$
|
177,076
|
$
|
(175,516
|
)
|
$
|
(13
|
)
|
$
|
1,553
|
|||||||||||
Cumulative effects of accounting change
|
2,500
|
2,500
|
||||||||||||||||||||||
Stock issued for cash at $4.00 - $4.04 per share, net
|
1,751,689
|
6,830
|
6,830
|
|||||||||||||||||||||
Stock-based compensation
|
887
|
887
|
||||||||||||||||||||||
Stock issued for vested RSUs
|
20,000
|
|||||||||||||||||||||||
Comprehensive income:
|
||||||||||||||||||||||||
Net Loss
|
(7,605
|
)
|
(7,605
|
)
|
||||||||||||||||||||
Other comprehensive income, net of tax
|
1
|
1
|
||||||||||||||||||||||
Comprehensive loss
|
(7,604
|
)
|
||||||||||||||||||||||
Balance at March 31, 2018
|
60,823,667
|
$
|
6
|
$
|
184,793
|
$
|
(180,621
|
)
|
$
|
(12
|
)
|
$
|
4,166
|
|||||||||||
Balance at December 31, 2018
|
66,879,847
|
$
|
7
|
$
|
208,317
|
$
|
(198,422
|
)
|
$
|
(14
|
)
|
$
|
9,888
|
|||||||||||
Stock issued for cash at $5.05 -$5.42 per share, net
|
560,338
|
2,848
|
2,848
|
|||||||||||||||||||||
Stock-based compensation
|
785
|
785
|
||||||||||||||||||||||
Exercise of options
|
663,816
|
816
|
816
|
|||||||||||||||||||||
Comprehensive income:
|
||||||||||||||||||||||||
Net Loss
|
(5,608
|
)
|
(5,608
|
)
|
||||||||||||||||||||
Other comprehensive loss, net of tax
|
1
|
1
|
||||||||||||||||||||||
Comprehensive loss
|
(5,607
|
)
|
||||||||||||||||||||||
Balance at March 31, 2019
|
68,104,001
|
$
|
7
|
$
|
212,766
|
$
|
(204,030
|
)
|
$
|
(13
|
)
|
$
|
8,730
|
Three Months Ended
|
||||||||
Cash flows from operating activities:
|
March 31,
2019
|
March 31,
2018
|
||||||
Net loss
|
$
|
(5,608
|
)
|
$
|
(7,605
|
)
|
||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Depreciation
|
2
|
6
|
||||||
Stock-based compensation
|
785
|
887
|
||||||
Changes in assets and liabilities:
|
||||||||
Accounts receivables
|
(2
|
)
|
(6
|
)
|
||||
Prepaid expenses and other assets
|
(201
|
)
|
(197
|
)
|
||||
Other liabilities
|
31
|
—
|
||||||
Accounts payable
|
229
|
3,331
|
||||||
Related party payable
|
—
|
258
|
||||||
Accrued payroll and related expenses
|
(54
|
)
|
(1,970
|
)
|
||||
Income tax liability
|
(1
|
)
|
5
|
|||||
Deferred revenue
|
—
|
2
|
||||||
Net cash used in operating activities
|
(4,819
|
)
|
(5,289
|
)
|
||||
Cash flows from investing activities:
|
||||||||
Purchase of investments
|
(2,283
|
)
|
(282
|
)
|
||||
Proceeds from sale or maturity of investments
|
1,054 |
1,154
|
||||||
Net cash (used in) provided by investing activities
|
(1,229
|
)
|
872
|
|||||
Cash flows from financing activities:
|
||||||||
Proceeds from exercise of options
|
816
|
—
|
||||||
Proceeds from sale of common stock
|
2,848
|
6,830
|
||||||
Payments of taxes on restricted stock units
|
—
|
(4
|
)
|
|||||
Net cash provided by financing activities
|
3,664
|
6,826
|
||||||
Net (decrease) increase in cash and cash equivalents
|
(2,384
|
)
|
2,409
|
|||||
Cash and cash equivalents, beginning of period
|
7,611
|
3,135
|
||||||
Cash and cash equivalents, end of period
|
$
|
5,227
|
$
|
5,544
|
||||
Cash paid for income taxes
|
$
|
2
|
$
|
—
|
||||
Non-Cash Transactions: |
||||||||
Deferred revenue reclassified to retained earnings - ASC 606 adoption
|
$ |
— | $ |
2,500 |
March 31, 2019
|
||||||||||||||||||||||||
Adjusted Cost
|
Unrealized
Gains
|
Unrealized
Losses
|
Fair Value
|
Cash and Cash
Equivalents
|
Investments
Available for
Sale
|
|||||||||||||||||||
Cash
|
$
|
3,867
|
$
|
—
|
$
|
—
|
$
|
3,867
|
$
|
3,867
|
$
|
—
|
||||||||||||
Level 1:
|
||||||||||||||||||||||||
Mutual funds
|
|
1,074
|
|
—
|
|
—
|
|
1,074
|
|
1,074
|
|
—
|
||||||||||||
U.S. agency securities
|
|
3,318
|
|
1
|
|
—
|
|
3,319
|
|
286
|
|
3,033
|
||||||||||||
|
4,392
|
|
1
|
|
—
|
|
4,393
|
|
1,360
|
|
3,033
|
|||||||||||||
Total
|
$
|
8,259
|
$
|
1
|
$
|
—
|
$
|
8,260
|
$
|
5,227
|
$
|
3,033
|
December 31, 2018
|
||||||||||||||||||||||||
Adjusted Cost
|
Unrealized
Gains
|
Unrealized
Losses
|
Fair Value
|
Cash and Cash
Equivalents
|
Investments
Available for
Sale
|
|||||||||||||||||||
Cash
|
$
|
5,048
|
$
|
—
|
$
|
—
|
$
|
5,048
|
$
|
5,048
|
$
|
—
|
||||||||||||
Level 1:
|
||||||||||||||||||||||||
Mutual funds
|
|
1,107
|
|
—
|
|
—
|
|
1,107
|
|
1,107
|
|
—
|
||||||||||||
U.S. agency securities
|
|
3,259
|
|
—
|
|
—
|
|
3,259
|
|
1,456
|
|
1,803
|
||||||||||||
|
4,366
|
|
—
|
|
—
|
|
4,366
|
|
2,563
|
|
1,803
|
|||||||||||||
Total
|
$
|
9,414
|
$
|
—
|
$
|
—
|
$
|
9,414
|
$
|
7,611
|
$
|
1,803
|
Original
Number
of
Warrants
Issued
|
Exercise
Price per
Common
Share
|
Exercisable at
December 31,
2018
|
Became
Exercisable
|
Exercised
|
Terminated /
Cancelled /
Expired
|
Exercisable
at March 31,
2019
|
Expiration
Date
|
||||||||||||||||||||||
25,000
|
$
|
7.00
|
25,000
|
—
|
—
|
—
|
25,000
|
April 2020
|
|||||||||||||||||||||
25,000
|
—
|
—
|
—
|
25,000
|
•
|
VirnetX Inc. v. The Mangrove Partners (USCAFC Case 17-1368)
|
• |
VirnetX Inc. v. Cisco Systems, Inc. (USCAFC Case 18-1197-CB) (Appeal of Apple I Case)
|
• |
VirnetX Inc. v. Apple Inc., Cisco Systems, Inc. (USCAFC Case 17-1591)
|
• |
VirnetX Inc. v. The Mangrove Partners (USCAFC Case 17-1368)
|
•
|
VirnetX Inc. v. Cisco Systems, Inc. (USCAFC Case 18-1197-CB) (Appeal of Apple I Case)
|
•
|
VirnetX Inc. v. Apple Inc., Cisco Systems, Inc. (USCAFC Case 17-1591)
|
• |
Although to date we have entered into a limited number of settlement and license agreements, we may not be successful in entering into further licensing relationships, or
if we are successful in entering into such relationships, the acquisition of them may be expensive, and they, as well as our existing settlement and our existing and pending license agreements may not generate the financial results we
expect;
|
• |
Third parties challenge to the validity of our patents;
|
• |
The pendency of our various litigations may cause potential licensees not to do business with us;
|
• |
Intense competition from new and established competitors who may have superior products and services or better marketing, financial or other capacities than we do; and
|
• |
The possibility that one or more of our potential customers or licensees develops or otherwise sources products or technologies similar to, competitive with or superior
to ours.
|
• |
New legislation, regulations or rules related to obtaining patents or enforcing patents could significantly increase our operating costs and decrease our revenue. For
instance, the United States Supreme Court has recently modified some tests used by the USPTO in granting patents during the past 20 years which may decrease the likelihood that we will be able to obtain patents and increase the
likelihood of challenge of any patents we obtain or license. In addition, the United States recently enacted sweeping changes to the United States patent system under the Leahy-Smith America Invents Act, including changes that
transition the United States from a “first-to-invent” system to a “first to file” system and alter the processes for challenging issued patents;
|
•
|
More patent applications are filed each year resulting in longer delays in getting patents issued by the USPTO;
|
•
|
Federal courts are becoming more crowded, and as a result, patent enforcement litigation is taking longer; and
|
•
|
As patent enforcement becomes more prevalent, it may become more difficult for us to voluntarily license our patents.
|
•
|
The need to educate potential customers about our patent rights and our product and service capabilities;
|
•
|
Our customers’ willingness to invest potentially substantial resources and modify their network infrastructures to take
advantage of our products;
|
• |
Our customers’ budgetary constraints;
|
• |
The timing of our customers’ budget cycles;
|
•
|
Delays caused by customers’ internal review processes; and
|
• |
Long sales cycles that may increase the risk that our financial resources are exhausted before we are able to generate significant revenue.
|
• |
Generate revenues or profit from product sales;
|
• |
Drive adoption of our products;
|
• |
Attract and retain customers for our products;
|
• |
Provide appropriate levels of customer training and support for our products;
|
• |
Implement an effective marketing strategy to promote awareness of our products;
|
• |
Focus our research and development efforts in areas that generate returns on our efforts;
|
• |
Anticipate and adapt to changes in our market; or
|
• |
Protect our products from any system failures or other breaches.
|
• |
Power loss, transmission cable cuts and other telecommunications failures;
|
• |
Damage or interruption caused by fire, earthquake, and other natural disasters;
|
• |
Computer viruses or software defects; and
|
• |
Physical or electronic break-ins, sabotage, intentional acts of vandalism, terrorist attacks and other events beyond our control.
|
• |
Developments or lack thereof in any then-outstanding litigation;
|
• |
Quarterly variations in our operating results;
|
• |
Large purchases or sales of common stock or derivative transactions related to our stock;
|
• |
Actual or anticipated announcements of new products or services by us or competitors;
|
• |
General conditions in the markets in which we compete; and
|
• |
General social, political, economic and financial conditions, including the significant volatility in the global financial markets.
|
•
|
Price and volume fluctuations in the overall stock market from time to time;
|
• |
Volatility in the market prices and trading volumes of companies in our industry or companies that investors consider comparable;
|
• |
Changes in operating performance and stock market valuations of other companies generally, or those in our industry;
|
• |
Sales of shares of our common stock by us or our stockholders;
|
• |
Failure of securities analysts to maintain coverage of us, changes in financial estimates by securities analysts who follow us, or our failure to meet these estimates or
the expectations of investors;
|
• |
The financial projections we may provide to the public, any changes in those projections or our failure to meet those projections;
|
• |
Announcements by us or our competitors of new products or services;
|
• |
The public’s reaction to our press releases, other public announcements and filings with the SEC;
|
• |
Rumors and market speculation involving us or other companies in our industry;
|
• |
Actual or anticipated changes in our results of operations;
|
• |
Actual or anticipated developments in our business, our competitors’ businesses or the competitive landscape generally;
|
• |
Litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors;
|
• |
Announced or completed acquisitions of businesses or technologies by us or our competitors;
|
• |
New laws or regulations or new interpretations of existing laws or regulations applicable to our business;
|
• |
Changes in accounting standards, policies, guidelines, interpretations or principles;
|
• |
Any significant change in our management; and
|
• |
General economic conditions and slow or negative growth of our markets.
|
• |
The outcome of actions to enforce our intellectual property rights currently in progress or that we may undertake in the future, and the timing thereof;
|
• |
The amount and timing of receipt of license fees from potential infringers, licensees or customers;
|
• |
The rate of adoption of our patented technologies;
|
• |
The number of new license arrangements we may execute, or that may expire, within a particular period and the scope of those licenses, including the number of our patents
which are licensed, the extent of prior infringement of our patent rights, royalty rates, timing of payment obligations, expiration date etc.;
|
• |
The success of a licensee in selling products that use our patented technologies; and
|
• |
The amount and timing of expenses related to our patent filings and enforcement proceedings, including litigation, related to our intellectual property rights.
|
• |
A staggered Board of Directors. This means that only one or
two directors (since we have a five-person Board of Directors) will be up for election at any given annual meeting. This has the effect of delaying the ability of stockholders to affect a change in control of us because it would take
two annual meetings to effectively replace a majority of the Board of Directors.
|
• |
Blank check preferred stock. Our Board of Directors has the authority to establish the rights, preferences and privileges of our 10,000,000 authorized, but unissued, shares of preferred stock.
Therefore, this stock may be issued at the discretion of our Board of Directors with preferences over your shares of our common stock in a manner that is materially dilutive to you. In addition, blank check preferred stock can be used
to create a “poison pill” which is designed to deter a hostile bidder from buying a controlling interest in our stock without the approval of our Board of Directors. We have not adopted such a “poison pill;” but our Board of Directors
has the ability to do so in the future, very rapidly and without stockholder approval.
|
• |
Advance notice requirements for director nominations and for new
business to be brought up at stockholder meetings. Stockholders wishing to submit director nominations or raise matters to a vote of the stockholders must provide notice to us within very specific date windows and in very
specific form in order to have the matter voted on at a stockholder meeting. This has the effect of giving our Board of Directors and management more time to react to stockholder proposals generally and could also have the effect of
disregarding a stockholder proposal or deferring it to a subsequent meeting to the extent such proposal is not raised properly.
|
• |
No stockholder actions by written consent. No stockholder or
group of stockholders may take actions rapidly and without prior notice to our Board of Directors and management or to the minority stockholders. Along with the advance notice requirements described above, this provision also gives
our Board of Directors and management more time to react to proposed stockholder actions.
|
• |
Super majority requirement for stockholder amendments to the By-laws. Stockholder proposals to alter or amend our By-laws or to adopt new By-laws can only be approved by the affirmative vote of at least 66 2/3% of
the outstanding shares of our common stock.
|
• |
No ability of stockholders to call a special meeting of the
stockholders. Only the Board of Directors or management can call special meetings of the stockholders. This could mean that stockholders, even those who represent a significant percentage of our shares of common stock, may
need to wait for the annual meeting before nominating directors or raising other business proposals to be voted on by the stockholders.
|
Exhibit
Number
|
Description
|
Certification of the President and Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
Certification of the President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
|
|
Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
|
101
|
Interactive Data Files
|
* |
This exhibit is furnished herewith, but not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to
liability under that section. Such certifications will not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except to the extent that we explicitly incorporate them by reference.
|
VIRNETX HOLDING CORPORATION
|
|||
By:
|
/s/ Kendall Larsen
|
||
Name
|
Kendall Larsen | ||
|
Chief Executive Officer (Principal Executive Officer)
|
By:
|
/s/ Richard H. Nance
|
||
Name
|
Richard H. Nance | ||
|
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
|
||
Date: May 10, 2019
|
/s/ Kendall Larsen
|
|
Kendall Larsen
|
|
President and Chief Executive Officer
|
|
(Principal Executive Officer)
|
|
Date: May 10, 2019
|
/s/ Richard H. Nance
|
|
Richard H. Nance
|
|
Chief Financial Officer
|
|
(Principal Financial Officer and Principal Accounting Officer)
|
|
Date: May 10, 2019
|
(1)
|
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
|
/s/ Kendall Larsen
|
|
Kendall Larsen
|
|
President and Chief Executive Officer
|
|
(Principal Executive Officer)
|
|
Date: May 10, 2019
|
(1)
|
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
|
/s/ Richard H. Nance
|
|
Richard H. Nance
|
|
Chief Financial Officer
|
|
(Principal Financial Officer and Principal Accounting Officer)
|
|
Date: May 10, 2019
|